Current Status of the Development of HIV Protease Inhibitors and Their Clinical Potential
- 1 December 1995
- journal article
- Published by Springer Nature in Clinical Immunotherapeutics
- Vol. 4 (6) , 451-461
- https://doi.org/10.1007/bf03259307
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995
- Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infectionNature, 1995
- Viral dynamics in human immunodeficiency virus type 1 infectionNature, 1995
- Update on a proteinase inhibitorAIDS, 1994
- Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease InhibitorsScience, 1994
- STRUCTURE-BASED INHIBITORS OF HIV-1 PROTEASEAnnual Review of Biochemistry, 1993
- Fidelity of HIV-1 reverse transcriptase copying RNA in vitroBiochemistry, 1992
- Kynostatin (KNI-227 and -272, highly potent anti-HIV agents: conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatine.CHEMICAL & PHARMACEUTICAL BULLETIN, 1992
- Design, Activity, and 2.8 Å Crystal Structure of a C 2 Symmetric Inhibitor Complexed to HIV-1 ProteaseScience, 1990
- Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analoguesNature, 1990